Dec 07, 2022 / 01:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead with us.
Just a reminder, personal analyst holding disclosures are available on morganstanley.com/researchdisclosures. And with that fun out of the way, Dan, thanks for being here. I thought maybe a good place to start off is we're sort of -- I guess you're 3 years into your tenure almost?
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Yes. Almost 4.
Questions and Answers:
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive DirectorAlmost 4, yes, that's right. And obviously, part of the -- when you came in, right, was a transformation of the company, right? You put a lot of capital to work on external assets. So where do you think you are in the transition of the company, sort
Trustpilot
